IBUPROFEN Injection

TRADE NAME

- Pedea.

INDICATION

- Prostaglandin inhibitor to treat patent ductus arteriosus.

DOSAGE RANGE GUIDELINES

- **Initial dose:** 10 mg/kg.
- **Second dose:** 5 mg/kg 24 hours later.
- **Third dose:** 5 mg/kg 48 hours after initial dose.
- Should not be given within 6 hours of birth.

ADVERSE EFFECTS

- Reduced urine output but less frequently observed compared to Indomethacin.
- Increased serum creatinine and urea.
- Platelet dysfunction and bleeding tendency.
- Cases of profound hypoxaemia have been noted when used prophylactically for ductal closure in the first 6 hours of life. Patients responded to inhaled nitric oxide.

COMMENTS

- Contraindicated in neonates with bleeding/coagulation defects (platelet count <60 000 x 10E9/L).
- If there is anuria or marked oliguria (<0.5 ml/kg/hour), withhold until renal function recovers.
- Caution with necrotising enterocolitis and hepatic disease and use of nephrotoxic drugs e.g. Gentamicin, Netilmicin, Vancomycin.
- Unlike Indomethacin, does not appear to reduce cerebral or mesenteric perfusion.
- Monitor urine output during treatment and check creatinine before and after completion of course.
FORMULATION

- Pedea ®, Orphan Europe.
- 2 ml ampoule of clear and colourless to slightly yellow solution containing 10 mg ibuprofen (5 mg/ml).

PREPARATION

- Draw up required amount of injection solution.

ADMINISTRATION

- Flush infusion line with 1.5 to 2 ml of either sodium chloride 0.9% or 5% glucose before and after infusion.
- Infuse over 15 minutes.
- Preferably infuse undiluted. If dilution is required the injection solution may be mixed with either sodium chloride 0.9% or 5% glucose.

STORAGE

- Discard unused portion.
- Store at room temperature.

RECORDING

- A list consisting of patient’s name, date and doctor prescribing must be kept at the back of the nursery admission book.

REFERENCES


Pedea ® Product Information. Orphan Europe.